Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study

Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study

Abstract Background Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 μg has been shown to improve lung function and health status, and reduce exacerbations, versus budesonide/formoterol in patients with chronic obstructive pulmonary disease (COPD). We evaluated the...

Full description

Bibliographic Details
Main Authors: Peter R. Bremner, Ruby Birk, Noushin Brealey, Afisi S. Ismaila, Chang-Qing Zhu, David A. Lipson
Format: Article
Language:English
Published: BMC 2018-01-01
Series:Respiratory Research
Subjects:
COPD
Exacerbations
FEV1
Lung function
Fluticasone furoate/umeclidinium/vilanterol
Randomized controlled trial
Online Access:http://link.springer.com/article/10.1186/s12931-018-0724-0

Internet

http://link.springer.com/article/10.1186/s12931-018-0724-0

Similar Items